Baxter International Inc. predicted that earnings will increase in 2014 after fourth-quarter sales gained 16 percent, boosted by demand for hemophilia treatments and medical products, as well as its acquisition of Gambro AB.

Adjusted earnings per share in 2014 will probably be $5.05 to $5.25, the Deerfield, Illinois-based company said today in a statement. The prediction may not compare to the average analyst estimate of $5.01 because it excludes intangible asset amortization expense that Baxter said will be about 25 cents.

Baxter said sales gained to $4.4 billion in the fourth quarter of 2013. Excluding Gambro, a Swedish competitor acquired to expand in kidney equipment, revenue rose 5 percent.

Revenue is predicted to gain 9 percent to 10 percent in 2014, without adjusting for currency fluctuations, the company said.